Investigational drugs and nutrients for human longevity. Recent clinical trials registered in ClinicalTrials.gov and clinicaltrialsregister.eu

@article{Garay2021InvestigationalDA,
  title={Investigational drugs and nutrients for human longevity. Recent clinical trials registered in ClinicalTrials.gov and clinicaltrialsregister.eu},
  author={Ricardo P Garay},
  journal={Expert Opinion on Investigational Drugs},
  year={2021},
  volume={30},
  pages={749 - 758}
}
  • R. Garay
  • Published 3 June 2021
  • Medicine, Biology
  • Expert Opinion on Investigational Drugs
ABSTRACT Introduction: Several pharmacological drugs have shown proof of concept for longevity in animal models. I aimed to identify and review those longevity drug candidates that are undergoing clinical trials. Areas covered: Recent (post-2017) longevity clinical trials were found in US and EU clinical trial registries. Longevity drug candidates are the antidiabetic drugs metformin and acarbose, and the immunosuppressant rapamycin. These medicinal drugs are tested on biochemical and clinical… 
View on Taylor & Francis
ncbi.nlm.nih.gov
8 Citations
Background Citations
1

8 Citations

Dietary Supplements and Natural Products: An Update on Their Clinical Effectiveness and Molecular Mechanisms of Action During Accelerated Biological Aging

It is suggested that dietary/natural products increase healthspan—rather than lifespan—effectively minimizing the period of frailty at the end of life, but real-world setting clinical trials and basic studies on dietary supplements and natural products are further required to decisively demonstrate whether dietary/ natural products could promote human lifespan.

Does Modulation of an Epigenetic Clock Define a Geroprotector?

It is argued that studies that enable understanding of the relationships between epigenetic clocks and disease processes while simultaneously testing the efficacy of a candidate geroprotector are crucial to move the field forward.

Molecular inhibition of RAS signalling to target ageing and age-related health

Evidence that RAS/MAPK signalling inhibitors already in clinical use, such as trametinib, acarbose, statins, metformin and dihydromyricetin, lead to lifespan extension and to improved healthspan is reviewed.

Mitochondrial and metabolic dysfunction in ageing and age-related diseases

The role of mitochondria in metabolism and how mitochondria contribute to age-related metabolic diseases is discussed, with a view to designing therapies targeting metabolic disorders to extend human health span and lifespan.

Human iPSC-Derived Neurons as A Platform for Deciphering the Mechanisms behind Brain Aging

An overview of age-related changes in the transcriptome, in signaling pathways, and in relation to epigenetic factors that occur in senescent neurons is provided and the potential of combining human iPSC-iNs with genome editing technology is focused on.

Nutraceuticals for Peripheral Vestibular Pathology: Properties, Usefulness, Future Perspectives and Medico-Legal Aspects

Nutraceuticals are often used in the treatment of dizziness and vertigo, but the rationale of their application is not always solidly demonstrated by the scientific evidence.

Role of Oxidative Stress in Ocular Diseases: A Balancing Act

It is posited that further development of therapeutic interventions to promote pro-regenerative responses and maintenance of the redox balance may delay or prevent the progression of these major ocular pathologies.

Progerin and Its Role in Accelerated and Natural Aging

Encouraging preliminary results achieved in purifying cells from progerin provide a means to develop an optimal procedure for periodic purification of the human body from progersin in order to reduce the rate of aging.

References

SHOWING 1-10 OF 102 REFERENCES

Investigational drugs in recent clinical trials for treatment-resistant depression

The authors describe the medications for treatment-resistant depression (TRD) in phase II/III of clinical development in the EU and USA and provide an opinion on how current treatment can be improved in the near future.

Metformin and Aging: A Review

Concerns exist not only for vitamin B12 and B6 deficiencies, but also about whether there are adverse effects of metformin on individuals who try to remain healthy by maintaining cardiovascular fitness via exercise.

A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs

The results showed no clinical side effects in the rapamycin-treated group compared to dogs receiving the placebo and echocardiography suggested improvement in both diastolic and systolic age-related measures of heart function in theRapamycin is tested on a larger dog cohort to determine whether it can significantly improve healthspan and reduce mortality in companion dogs.

Metformin improves healthspan and lifespan in mice

It is shown that long-term treatment with metformin starting at middle age extends healthspan and lifespan in male mice, while a higher dose (1% w/w) was toxic.

The D-Health Trial: A randomized trial of vitamin D for prevention of mortality and cancer.

Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults

This study provides the first evidence that, in older adults, metformin has metabolic and nonmetabolic effects linked to aging, and identifies a cascade of predictive upstream transcriptional regulators that may explain tissue‐specific transcriptomic changes in response to met formin treatment.

Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials.

BACKGROUND Ecological and observational studies suggest that low vitamin D status could be associated with higher mortality from life-threatening conditions including cancer, cardiovascular disease,…

Measuring biological aging in humans: A quest

Current research focuses on measuring the pace of aging to identify individuals who are “aging faster” to test and develop interventions that could prevent or delay the progression of multimorbidity and disability with aging.

Investigational drugs for treating agitation in persons with dementia

Of the compounds in phase II clinical trials, ELND005 (scyllo-inositol) is intended to progress into phase III development, based on evidence from a subgroup analysis and biomarker data.

Metformin Retards Aging in C. elegans by Altering Microbial Folate and Methionine Metabolism

...